Matinas BioPharma Holdings, Inc. (MTNB)
After hours:
| Previous close | 0.1815 |
| Open | 0.1808 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 800 |
| Day's range | 0.1772 - 0.1850 |
| 52-week range | 0.1100 - 0.8900 |
| Volume | |
| Avg. volume | 1,565,556 |
| Market cap | 45.598M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1100 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.00 |
GlobeNewswireMatinas BioPharma Prices $10 Million Registered Direct Offering
BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 p
Insider MonkeyMatinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript March 28, 2024 Matinas BioPharma Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome, everyone, to the Matinas BioPharma 2023 Financial Results Conference Call. Currently, all participants are […]
- Thomson Reuters StreetEvents
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
Q4 2023 Matinas BioPharma Holdings Inc Earnings Call
